RxDoctor Payments Data

Barbara Clinkenbeard, APRN

Psychiatric/Mental Health · Bellevue, NENPI 1497761415

Payments from drug & device makers

$2,599in general payments, 2019–2025

Across 89 payments — averaging $29.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Axsome Therapeutics, Inc.$613
  • AbbVie$256
  • Vanda Pharmaceuticals Inc.$170
  • Lundbeck LLC$96
  • Johnson & Johnson$61
  • plus $129 from 5 others

What the payments were for

  • Food & beverage$2,599100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,599 in reported general payments places this provider in the 70th percentile of 255 psychiatric/mental health providers in Nebraska.

See all psychiatric/mental health providers in Nebraska

Medicare billing

Part B allowed, 2024
$13,166
Medicare patients
27
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl12$16,634
Desvenlafaxine Succinate ErDesvenlafaxine Succinate58$2,516
Lisdexamfetamine Dimesylate11$1,840
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine24$1,208
Bupropion XlBupropion Hcl54$779
Mirtazapine31$609
Trazodone Hcl66$587
Lamotrigine37$535
Buspirone Hcl20$389
Temazepam44$370
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine14$338
Quetiapine Fumarate21$311
Alprazolam72$298
Duloxetine Hcl12$190
Lorazepam24$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$256$16,63412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 255 psychiatric/mental health providers in Nebraska.

Other psychiatric/mental health in Bellevue

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →